|
Plerixafor Clinical Trials
5 actively recruiting trials across 5 locations
Also known as: AMD 3100, LM-3100, Mobozil, Mozobil
Pipeline
Phase 1: 1Phase 2: 2Phase 1/2: 2
Top Sponsors
- Washington University School of Medicine1
- Thomas Jefferson University1
- Stanford University1
- National Cancer Institute (NCI)1
- M.D. Anderson Cancer Center1
Indications
- Cancer5
- Multiple Myeloma2
- Pre-transplant Purging1
- Post-transplant MRD-guided Maintenance Therapy1
- Acute Myeloid Leukemia, Pediatric1
Stanford, California1 trial
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
Phase 1
Bethesda, Maryland1 trial
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
National Institutes of Health Clinical Center
Phase 1/2
St Louis, Missouri1 trial
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Washington University School of Medicine
Phase 1/2
Philadelphia, Pennsylvania1 trial
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University Hospital
Phase 2
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.